Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts ...
Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut ...
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...
Merck (NYSE:MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda. The Rahway, New Jersey-based company announced Tuesday ...
Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. The multiyear effort comes as Merck prepares to ...
Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut administrative, ...
New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon ...
The consensus narrative frames Merck as a one-product company facing an existential patent cliff in 2028. Wefundamentally disagree with this characterization. Merck is executing one of the most ...
Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. Stream Los Angeles News for free, 24/7, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results